Funding Archives

cancer cell screening drug discovery microplate

News and Trends 26 Oct 2022

Recursion announces $150M private placement

U.S. biotech Recursion Pharmaceuticals has entered into a stock purchase agreement for the sale of an aggregate of approximately 15.3 million shares of its Class A common stock in a private placement. It was led by Kinnevik AB, with participation by Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus, and Platinum Asset Management. The […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Enhanc3D Genomics raises £10M to advance technology platform

Enhanc3D Genomics, a functional genomics company, has raised £10 million ($11.2 million) in series A financing. The funds will be used to accelerate the development of its proprietary technology platform – GenLink3D. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures. The funding will enable Enhanc3D […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Immunethep receives European Innovation Council funding for clinical trials

Immunethep, a Portuguese biotech startup, has been selected by the European Innovation Council (EIC) to receive funding from its EIC Accelerator program. Immunethep will receive initially a €2.5 million ($2.5 million) grant and is eligible for additional equity investment from the EIC Fund for a project with a total investment of €17.5 million ($17.1 million). […]

October 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Aqemia raises €30M for AI-enabled drug discovery pipeline

Aqemia has raised €30 million ($29.5 million) in a series A funding round to scale up drug discovery, through a first-in-class technological platform combining quantum-inspired physics and machine learning. The funding was led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of previous investor Elaia. In three years, Aqemia has grown […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Nucleome Therapeutics raises £37.5M to deliver precision medicines

U.K. biotech company Nucleome Therapeutics Limited has closed an oversubscribed £37.5 million ($42.4 million) series A financing round. The funds will be used to advance the company’s autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The financing was led by new investor M Ventures, the strategic, corporate […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 14 Oct 2022

Mablink Bioscience receives €31M series A funding for ADC pipeline

French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody drug conjugates (ADCs). The round was led by Sofinnova Partners and Mérieux Equity Partners. Existing shareholders Elaia Partners, UI-Investissement/Pertinence Invest 2 (advised by Mérieux Equity […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment

The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has invested in Samsara Therapeutics Inc. Samsara Therapeutics is a biotech company focusing on discovering and developing therapeutics to restore autophagy – the process by which cells recycle damaged or dysfunctional components. Samsara is developing several novel, […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Biotech company Odyssey Therapeutics, Inc. has announced it has raised $168 million in series B financing. Odyssey Therapeutics is working on next generation precision immunomodulators and oncology medicines. The current round brings the total capital raised to $386 million. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

Araris Biotech closes $24M financing round for ADCs

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review. The study, “Improving the Efficiency of […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia

The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA vaccine projects at the University of British Columbia (UBC). The funding, through the Pacific Economic Development Agency of Canada (PacifiCan), is for UBC to enhance the delivery and efficacy of mRNA vaccines. PacifiCan is investing the money through its Regional […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

NeuShen Therapeutics closes $20M pre-A financing

Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing led by LAPAM, a China based venture capital. The new capital will be used to expand the team and catalyze in-house CNS (central nervous system) drug discovery in both the U.S. and China. “The successful completion of this fundraising is […]

September 29, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Funding

Recursion announces $150M private placement

Enhanc3D Genomics raises £10M to advance technology platform

Immunethep receives European Innovation Council funding for clinical trials

Aqemia raises €30M for AI-enabled drug discovery pipeline

Nucleome Therapeutics raises £37.5M to deliver precision medicines

Mablink Bioscience receives €31M series A funding for ADC pipeline

CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment

Odyssey Therapeutics raises $168M for oncology medicine portfolio

Araris Biotech closes $24M financing round for ADCs

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia

NeuShen Therapeutics closes $20M pre-A financing

Subscribe to our newsletter to get the latest biotech news!